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Abstract
In 216 patients who underwent stereotactic irradiation (STI), MRI was performed 4–12 times for 17–29 months after STI. Frequency of
new radiation-induced lesions more than 2 cm in diameter on sequential MRI following STI, and characteristics on sequential MRI findings
were investigated. Ten patients displayed new lesions following STI. These patients comprised eight of 208 patients with intracranial
neoplasm and two of seven patients with AVM. Lesions appeared 1–12 months after STI. The lesions appeared near primary lesions in nine
patients. Contrast-enhancement was seen along the cerebral cortex in three patients. Sequential MRI is effective in detecting radiation-
induced lesions following STI.
q 2004 Elsevier Ltd. All rights reserved.
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radiosurgery (SRS) and fractionated stereotactic radio-
therapy (SRT), represents a more effective treatment for
neoplasms and arteriovenous malformations (AVMs) of the
brain than conventional radiotherapy. Therapeutic results
have been reported in numerous cases with primary
malignant and benign tumors, metastatic tumors of the
brain, AVMs of the brain, and pain disorders [1–8].
Although the procedure is non-invasive, adverse effects
following STI have been reported in patients with AVM
[9,10] or tumors [10]. Symptomatic sequelae including
minor symptoms such as headache and vertigo have been
reported from several to 30% of patients [9–11]. Imaging
changes on means of CT, MRI, single photon emission
computed tomography (SPECT), and positron emission
tomography (PET) of targeted lesions have also been
reported [12–15], but sequential changes on MRI in the
tissue surrounding targeted lesions with or without symp-
toms have not been sufficiently reported. The present study1572-3496/$ - see front matter q 2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.compmedimag.2004.10.003
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E-mail address: tomura@med.akita-u.ac.jp (N. Tomura).investigated the frequency and characteristics of new
radiation-induced lesions on sequential MRI following STI.1. Materials and methods
A total of 216 patients underwent STI in our hospital
between June 2000 and April 2003. These comprised 208
patients with tumors of the brain, seven patients with AVM,
and one patient with trigeminal neuralgia. Tumors included
metastatic tumor (nZ107), glioblastoma (nZ21), anaplas-
tic astrocytoma (nZ10), meningioma (nZ22), acoustic
schwannoma (nZ8), pituitary adenoma (nZ13), malignant
lymphoma (nZ6), and others (nZ21). SRS were performed
in 81 patients, and 108 patients received SRT. Both SRS and
SRT were used in 27 patients. SRS delivered to the margin
of the lesion with a range of 8.3–62.4 Gy and maximum
doses ranged from 10.6 to 80.0 Gy. Target volume for SRS
ranged from 0.03 to 20.6 cm3. SRT delivered to the margin
of the lesion with a range of 9.9–45.4 Gy and maximum
doses ranged from 15.0 to 62.4 Gy. Number of fractions in
SRT ranged from 4 to 20. Target volume for SRT ranged
from 0.18 to 88.7 cm3. SRS and SRT were performed usingCMIG Extra: Cases 28 (2004) 73–79www.elsevier.com/locate/compmedimag
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and a noninvasive frame for SRT were used. For the
noninvasive frame, a patient-specific mask was attached to a
stereotactic frame. Treatment planning was performed using
contrast-enhanced T1-weighted imaging (T1WI), contrast-
enhanced CT, and/or conventional angiography, and plan-
ning software. MRI was performed 4–12 times (mean, 5.6)
for 17–29 months (mean, 21 months) after STI. MRI
after STI included axial spin-echo (SE) T1WI (380–680/
9–14/4[repetition time (ms)/echo time (ms)/number of
excitations]; 4-mm slice thickness; 2-mm interslice gap),
axial fast SE T2-weighted imaging (T2WI) (3600–4500/
96–105[effective]/2; echo train length (ETL)Z10–16;
4-mm slice thickness; 2-mm interslice gap), fast SE fluid-
attenuated inversion-recovery (FLAIR) (1002/148–162/1,
inversion time (TI)Z2200, ETLZ8, 4-mm slice thickness,
2-mm interslice gap), and contrast-enhanced T1WI after
intravenous administration of 0.2 mmol/kg body weight
gadopentitate dimeglumine (Gd) (Magnevist, Berlex Ima-
ging, Wayne, NJ, USA). Frequency and characteristics of
new radiation-induced lesions more than 2 cm in diameter
on sequential MRI following STI were investigated.2. Results
Ten patients (4.6%) displayed new radiation-induced
lesions more than 2 cm in diameter on sequential MRI
following STI. Those patients are summarized in Tables 1
and 2, and comprised of 8 of 208 patients (3.8%) with
intracranial neoplasm and 2 of 7 patients (28.6%) with
AVM. Intracranial neoplasms were two with meningiomas,
one central neurocytoma, one glioblastoma, one anaplastic
astrocytoma, one cavernous angioma, one atypical teratoid
rhabdoid tumor, and one primitive neuroectodermal tumor.
SRS (maximum dose: 16.4–20.2 Gy; marginal dose: 12.6–
15.6 Gy; target volume: 1.2–5.0 cm3) was delivered in 3Table 1
Primary lesions of patients
Case Age/sex Disease Location of
primary lesion
1 24/M CN rt. lateral ventricle
2 43/F GBM lt. parietal
3 48/M AVM lt. frontal, parietal
4 50/M Meningioma lt. parietal, occipital
5 56/F CA lt. parasellar
6 69/F Meningioma rt. parietal, occipital
7 57/M AA lt. T-P-O
8 31/F AVM lt. basal ggl., thalamus
9 17/F ATRT lt. frontal
10 15/F PNET lt. frontal
M, male; F, female; CN, central neurocytoma; GBM, glioblastoma; AVM, arteriov
PNET, primitive neuroectodermal tumor; rt., right; lt., left; ATRT, a typical tera
stereotactic radiosurgery; SRT, fractionated stereotactic radiotherapy.patients, and SRT (maximum dose: 20.0–62.4 Gy; marginal
dose: 16.2–43.8 Gy; target volume: 3.9–38.1 cm3; number
of fractions: 4–15) was delivered in seven patients.
Radiation-induced lesions were seen in three of 81 patients
(3.7%) who received SRS, and in seven of 135
patients (5.2%) who received SRT or both SRT and SRS.
The lesions appeared 1–12 months (mean, 6.0 months) after
STI. Eight of the 10 patients were asymptomatic following
STI. When new lesions occurred, one patient with
glioblastoma and another with meningioma developed
convulsive seizures that were controlled using steroids. In
nine patients, radiation-induced lesions appeared near
primary lesions (Fig. 1), but one patient with meningioma
displayed a lesion in the contralateral cerebral hemisphere
(Fig. 2). Lesions were located in the superior and medial
side of the frontal or parietal lobe in seven patients. Lesions
appeared hyperintense on T2WI in every patient, and
hypointense in nine patients and hyperintense in one patient
on T1WI. Contrast-enhanced T1WI showed contrast
enhancement along the cerebral cortex in four patients. In
six patients, lesions began to swell 1–3 months after STI and
continued for 1–4 months. Radiation dose to the area of the
lesion ranged from 4.0 to 24.0 Gy (mean, 8.4 Gy). Two
patients with AVM revealed new lesions when shrinkage of
AVM was seen following STI.3. Discussion
Radiation effects have generally been divided into acute,
subacute, and chronic phases [16]. The acute phase is first 2
months following irradiation, the subacute occurs from 2 to
6 months, and the chronic is after 6 months. In the present
study, sequential MRI was performed within 29 months
following STI. New lesions appeared in the acute phase in
one patient, in the subacute phase in five, and in the chronic
phase in four. Of the seven patients with AVM, twoNumber of
fractions
Target lesion
Maximum
dose (Gy)
Marginal
dose (Gy)
Volume
(cm3)
1 (SRS) 20.2 15.0 1.2
15 (SRT) 62.4 43.8 38.1
1 (SRS) 20.0 15.6 5.0
4 (SRT) 28.0 20.7 10.8
5 (SRT) 25.0 16.8 14.8
1 (SRS) 16.4 12.6 4.5
5 (SRT) 37.0 19.0 32.6
4 (SRT) 30.0 23.1 3.9
4 (SRT) 20.0 16.2 22.7
5 (SRT) 27.0 19.3 26.5
enous malformation; CA, cavernous angioma; AA, anaplastic astrocytoma;
toid rhabdoid tumor; T-P-O, temporo-parieto-occipital; ggl., ganglia; SRS,
Table 2
Radiation-induced lesions following STI
Case Location T1WI T2WI CE Duration from
end of STI to
appearance of
new lesions
Radiation dose to
new lesions after
STI (Gy)
Clinical symp-
toms after STI
Swelling of new
lesions
1 Corpus callosum hypo hyper C 6 mos. 4.0 K C
2 lt. superior part of
fr. and pr.
hypo hyper C 8 mos. 24.0 C C
3 lt. superior part of
frontal
hypo hyper C 12 mos. 6.0 K C
4 lt. superior part of
parietal
hypo hyper K 3 mos. 8.4 C C
5 lt. frontal and
temporal base
hypo hyper K 6 mos. 7.5 K C
6 rt. superior part of
parietal
hypo hyper C 9 mos. 4.0 K C
7 lt. superior part of
parietal
iso hyper C 9 mos. 6.5 K K
8 lt. deep part of
temporal
hyper hyper C 3 mos. 12.0 K K
9 lt. superior part of
frontal
hypo hyper C 3 mos. 6.0 K K
10 lt. frontal hypo hyper K 1 mos. 5.4 K K
STI, stereotactic irradiation; T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; fr., frontal; pr., parietal; hypo, hypointense; iso, isointense; hyper,
hyperintense; CE, contrast enhancement; mos., months; lt., left; rt., right.
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clinical symptoms. Frequency of MR imaging changes in
the present study was higher in patients with AVM than in
those with intracranial tumors. Previously, several authors
have reported a higher incidence of imaging changes and
symptomatic sequelae in patients with AVM than in patients
with brain tumors [8–11,17]. Smyth et al. [17] reported that
37% of patients with AVM exhibited enlargement of
hyperintense areas on T2WI after SRS, and 6% of patients
exhibited symptomatic edema. Frequency of new lesions
following STI in patients with AVM in the present study
was 28.6%, a similar result to the previous reports [8,17].
Dose and volume for the target contribute substantially to
the risk of post-radiosurgery sequelae in patients with AVM.
Flickinger et al. [9] reported that a significant difference in
occurrence of sequelae between patients receiving mini-
mum nidus doses of !20 Gy and patients O20 Gy. Chang
et al. [18] also pathologically confirmed that 33% of patients
with AVM receiving SRS displayed radiation-induced
necrosis in adjacent brain tissue. They confirmed a
significant correlation between extent of radiation-induced
changes and dose of radiation received, and patients
receiving 20 Gy developed moderate to severe radiation
vascular changes. However, their study did not use SRT,
only SRS. Two patients with AVM in the present study
received 20 Gy or more for the targeted lesion. One possible
explanation is that hemodynamic changes result from
changes to AVM vessels [9]. Two patients with AVM in
the present study exhibited new lesions when shrinkage of
AVMs was seen following STI. Generally, complete
obliteration of cerebral AVM can occur from 4 months to
5 years after SRS [19]. In the present study, the two AVMsshrank at 3 and 12 months following STI, respectively. SRS
and SRT are believed to result in obliteration of cerebral
AVMs by endothelial cell proliferation, progressive wall
thickening, and eventual luminal closure [20]. New lesions
seen in our patients may be due to vasoocclusive effects in
the tissue surrounding AVMs, as well as hemodynamic
changes resulting from obliteration of AVMs. Sequential
MRIs can benefit patients with AVM receiving STI to
monitor therapeutic response, as intensity patterns of
surrounding brain can be shown, in addition to morpho-
logical patterns of AVMs such as intensities and volumes of
niduses, and intensities of feeders and drainers. If MRI
findings are suggestive of complete obliteration, conven-
tional angiography should be performed. Controversy
remains regarding how long sequential MRIs should be
performed after STI. Some authors [21,22] have already
reported cases of complete obliteration occurring more than
60 months after STI. Further investigation will be needed to
clarify how long MRIs should be examined after STI.
The mechanisms of occurrence for new radiation-induced
lesions in the brain surrounding tumors may differ somewhat
from those in patients with AVM. Transient enlargement and
contrast enhancement of tumors, particularly benign tumors,
following STI has been reported [13,14]. This may be due to
radiation-induced deficiencies of the blood–brain barrier
(BBB), and is sometimes difficult to distinguish from
progressive growth of the tumors. However, differentiation
is obviously clinically important. If the tumor is undergoing
progressive growth, patients may need further radiation
therapy. Transient enlargement of tumors following STI was
not observed in the present study. This may be due to the
small number of patients that underwent SRS, as transient
Fig. 1. A 48-year-old man with arteriovenous malformation (AVM) (Case 3, Tables 1 and 2). Vascular flow voids mainly in the left central sulcus are seen on
T2-weighted imaging (T2WI) before stereotactic radiotherapy (SRT) (A, arrows). T2WI 12 months after SRT (B) shows diminished flow voids and a new
hyperintense lesion in the left precentral gyrus (arrow). T2WI 15 months after SRT (C) reveals increased size of the hyperintense lesion (arrows). T2WI 21
months after SRT (D) shows decreased size of the lesion and disappearance of vascular flow voids.
N. Tomura et al. / CMIG Extra: Cases 28 (2004) 73–7976enlargement of tumor is more often seen in SRS than in SRT
[23]. However, radiation-induced lesions in the surrounding
brain that appeared following STI attributed to disruption of
the BBB in the surrounding brain, caused by vascular
endothelial injury [12,18,20]. MRI findings were hypoin-
tensity on T1WI and hyperintensity on T2WI in most
patients. One patient (Case 7, Table 2) showed isointensity
and another patient (Case 8) showed hyperintensity on
T1WI. Swelling of lesions was seen in six patients, with two
patients complaining of clinical symptoms. Lesions began to
swell 1–3 months after STI and continued for 1–4 months.
Swelling persisting for a relatively long time seems
characteristic of radiation injury. Contrast enhancement
mainly along the cortex was seen in four patients. High
intensity areas on T1WI may be due to radiation vasculitis,necrosis and hemorrhage [18]. A previous study comparing
MRI and histopathology confirmed the existence of
telangiectatic vessels in the subcortical and cortical regions
[15]. Contrast enhancement was mainly seen along the
cortex in the present study, and may be due to telangiectatic
vessels. These telangiectatic vessels, which have been
proposed to result from microvascular occlusion, may
provide a source of hemorrhage [24]. Occurrence of clinical
symptoms depends on the location, size, and severity of
damage in the lesion. This is likely to depend on the mapping
and dose of irradiation. In two patients with clinical
symptoms, 24 Gy with 15 fractions (Case 2, Table 2) and
8.4 Gy with four fractions (Case 4, Table 2) were
administered to lesions that appeared after STI. The dose
received by one of these patients was not low (24 Gy),
Fig. 2. A 69-year-old woman with residual meningioma in the parietal convexity after surgery (Case 6, Tables 1 and 2). MRI before SRT shows hyperintensity
on T2WI (A, white arrow), a hypointense lesion on T1WI (B, white arrow), and slightly contrast enhancement near the operated site on contrast-enhanced
T1WI (C). MRI 9 months after SRT reveals a new lesion (arrows) with moderate swelling in the contralateral hemisphere on T2WI (D) and T1WI (E), and
contrast enhancement (arrows) along the cortex on contrast-enhanced T1WI (F).
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targeted lesions in the two patients complaining of new
clinical symptoms after STI were not definitely different
from other patients without radiation-induced lesions
following STI, so why these two patients displayed new
lesions following STI remains unclear. However, three
patients with new lesions after receiving SRS had no clinical
symptoms. The correlation among occurrence of clinical
symptoms, SRS, and SRT is also unclear. The present study
was performed in a small number of subjects. The
relationship between radiation dose, target volume, fraction
size, and imaging changes should be further investigated.4. Summary
Frequency and characteristics of new radiation-induced
lesions more than 2 cm in diameter on sequential MRI
following stereotactic irradiation (STI) were investigated in
the present study. A total of 216 patients underwent STI
between June 2000 and April 2003. These comprised 208
patients with tumors of the brain, seven patients with AVM,
and one patient with trigeminal neuralgia. Tumors included
metastatic tumor (nZ107), glioblastoma (nZ21), anaplas-
tic astrocytoma (nZ10), meningioma (nZ22), acoustic
schwannoma (nZ8), pituitary adenoma (nZ13), malignant
lymphoma (nZ6), and others (nZ21). Stereotactic radio-
surgery (SRS) were performed in 81 patients, and 108
patients received stereotactic radiotherapy (SRT). Both SRS
and SRT were used in 27 patients. MRI was performed 4–12
times (mean, 5.6) for 17–29 months (mean, 21 months) after
STI. MRI after STI included T1-weighted imaging (T1WI),
T2-weighted imaging (T2WI), fast SE fluid-attenuated
inversion-recovery (FLAIR), and contrast-enhanced
T1WI. Ten patients (4.6%) displayed new radiation-induced
lesions more than 2 cm in diameter on sequential MRI
following STI. Those patients comprised of eight of 208
patients (3.8%) with intracranial neoplasm and two of
seven patients (28.6%) with AVM. SRS (maximum dose:
16.4–20.2 Gy; marginal dose: 12.6–15.6 Gy; target volume:
1.2–5.0 cm3) was delivered in three patients, and SRT
(maximum dose: 20.0–62.4 Gy; marginal dose: 16.2–
43.8 Gy; target volume: 3.9–38.1 cm3; number of fractions:
4–15) was delivered in seven patients. Radiation-induced
lesions appeared 1–12 months (mean, 6.0 months) after STI.
Although eight of the 10 patients were asymptomatic
following STI, two patients developed convulsive seizures.
In nine patients, radiation-induced lesions appeared near
primary lesions, but one patient with meningioma displayed
a lesion in the contralateral cerebral hemisphere. Lesions
were located in the superior and medial side of the frontal or
parietal lobe in seven patients. Lesions appeared hyper-
intense on T2WI in every patient, and hypointense in nine
patients and hyperintense in one patient on T1WI. Contrast-
enhanced T1WI showed contrast enhancement along the
cerebral cortex in four patients. In six patients, lesions beganto swell 1–3 months after STI and continued for 1–4
months. Radiation dose to the area of the lesion ranged from
4.0 to 24.0 Gy (mean, 8.4 Gy). Two patients with AVM
revealed new lesions when shrinkage of AVM was seen
following STI. In two patients with clinical symptoms,
24 Gy with 15 fractions and 8.4 Gy with four fractions were
administered to lesions that appeared after STI. The dose
received by one of these patients was not low (24 Gy), but
fraction size was not high (1.6 Gy). Volume and dose for
targeted lesions in the two patients complaining of new
clinical symptoms after STI were not definitely different
from other patients without radiation-induced lesions
following STI. Why these two patients displayed new
lesions following STI remains unclear. The relationship
between radiation dose, target volume, fraction size, and
imaging changes should be further investigated.References
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